BioLineRx (NASDAQ:BLRX) Stock Price Crosses Above 200-Day Moving Average – Time to Sell?

BioLineRx Ltd. (NASDAQ:BLRX) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.87 and traded as high as $3.32. BioLineRx shares last traded at $3.16, with a volume of 7,860 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioLineRx in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, BioLineRx has an average rating of “Sell”.

BioLineRx Stock Up 4.6%

The company has a debt-to-equity ratio of 0.16, a current ratio of 1.58 and a quick ratio of 1.43. The firm has a 50-day simple moving average of $2.91 and a two-hundred day simple moving average of $2.87. The company has a market cap of $13.81 million, a PE ratio of -1.65 and a beta of 1.53.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.68. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.The business had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.34 million.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.